Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, No. 127 West Changle Road, Xi'an, 710032, Shaanxi Province, People's Republic of China.
Clin Rheumatol. 2018 Jan;37(1):5-11. doi: 10.1007/s10067-017-3820-5. Epub 2017 Sep 25.
Osteonecrosis (ON) is one of the serious complications for systemic lupus erythematosus (SLE); we aimed to study the risk relationship between disease activity and incidence of ON in SLE patients. The PubMed, Embase, and Cochrane library databases were searched for papers published up to May 2016 with English-language restriction; studies that compared disease activity between SLE patients with and without ON would be included, and eight studies involving a total of 1119 SLE patients were included. The incidence of ON in SLE was significantly associated with high patient's disease activity, including the degree (pool odds ratio 2.54, 95% confidence interval [CI] [1.33, 4.86], p = 0.005) and the scores (mean difference 2.33, 95% CI [0.86, 3.80], p = 0.002). Besides, immunosuppressive drug use was also a significant risk factor for ON (p = 0.00001), while antimalarial treatment played a protective role (p = 0.01). No evidence of publication bias was detected. In conclusion, disease activity is a significant and independent risk factor for ON, and higher disease activity score is associated with accelerated incidence of ON in SLE patients.
骨坏死(ON)是系统性红斑狼疮(SLE)的严重并发症之一;我们旨在研究疾病活动与 SLE 患者 ON 发生率之间的风险关系。检索了截至 2016 年 5 月的 PubMed、Embase 和 Cochrane 图书馆数据库,限制使用英文语言;将纳入比较 SLE 患者中有无 ON 的疾病活动的研究,共纳入了 8 项研究,共涉及 1119 例 SLE 患者。SLE 患者的 ON 发生率与患者的疾病活动度显著相关,包括疾病程度(汇总优势比 2.54,95%置信区间[CI] [1.33, 4.86],p = 0.005)和评分(平均差异 2.33,95% CI [0.86, 3.80],p = 0.002)。此外,免疫抑制剂的使用也是 ON 的一个显著危险因素(p = 0.00001),而抗疟治疗则发挥了保护作用(p = 0.01)。未发现发表偏倚的证据。总之,疾病活动度是 ON 的一个显著和独立的危险因素,更高的疾病活动评分与 SLE 患者 ON 的加速发生率相关。